FibroGen (NASDAQ:FGEN) Given “Buy” Rating at HC Wainwright

FibroGen (NASDAQ:FGEN)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $10.00 target price on the biopharmaceutical company’s stock.

Several other equities analysts have also weighed in on the stock. William Blair reissued a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th. StockNews.com began coverage on shares of FibroGen in a report on Thursday, February 13th. They issued a “hold” rating on the stock.

FibroGen Trading Down 8.6 %

FGEN opened at $0.71 on Thursday. The stock’s fifty day simple moving average is $0.52 and its 200 day simple moving average is $0.43. FibroGen has a 1-year low of $0.18 and a 1-year high of $2.80. The stock has a market cap of $71.13 million, a PE ratio of -0.57 and a beta of 0.75.

Institutional Trading of FibroGen

Institutional investors have recently added to or reduced their stakes in the company. Two Sigma Securities LLC acquired a new stake in shares of FibroGen during the fourth quarter worth $27,000. Velan Capital Investment Management LP bought a new position in FibroGen during the fourth quarter worth about $42,000. XTX Topco Ltd increased its position in FibroGen by 423.8% during the fourth quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 77,693 shares during the period. Franklin Street Advisors Inc. NC raised its stake in FibroGen by 100.0% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 100,000 shares in the last quarter. Finally, FMR LLC boosted its holdings in FibroGen by 21.8% in the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 68,569 shares during the period. 72.71% of the stock is currently owned by institutional investors.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.